Effect of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor on Disease Activity in Patients With Rheumatoid Arthritis
Authors:
- Yu-Feng YinYYYu-Feng Yin
- Li-Dan ZhaoLZLi-Dan Zhao
- Li WangLWLi Wang
- Wen-Jie ZhengWZWen-Jie Zheng
- Hua ChenHCHua Chen
- Qing-Jun WuQWQing-Jun Wu
- Fu-Lin TangFTFu-Lin Tang
- Feng-Chun ZhangFZFeng-Chun Zhang
- Guangliang ShanGSGuangliang Shan
- Xuan ZhangXZXuan Zhang
Open Access
- 1 February 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (8) , e572
Abstract
HMG-CoA reductase inhibitors (also known as statins) are widely used as lipid-lowering agents in patients with rheumatoid arthritis (RA) to reduce their cardiovascular risk. However, whether they have an effect on RA disease activity is controversial. This study aimed to investigate the effect of statins on disease activity in RA patients. A systematic literature review was performed using the MEDLINE, EMBASE, Cochrane Library, ISI WEB of Knowledge, Scopus, and Clinical Trials Register databases. Only prospective randomized controlled trials or controlled clinical trials comparing the efficacy of statins with placebo on adult RA patients were included. The efficacy was measured according to the ACR criteria, EULAR criteria, DAS28, HAQ score, ESR, or CRP. The Jadad score was used for quality assessment. The inverse variance method was used to analyze continuous outcomes. A fixed-effects model was used when there was no significant heterogeneity; otherwise, a random-effects model was used. For stability of results, we performed leave-one-study-out sensitivity analysis by omitting individual studies one at a time from the meta-analysis. Publication bias was assessed using Egger test. A total 13 studies involving 737 patients were included in the meta-analysis; 11 studies were included in the meta-analysis based on DAS28, while the other 2 studies were only included in the meta-analysis based on ESR or CRP. The standardized mean difference (SMD) in DAS28 between the statin group and the placebo group was −0.55 (95% CI [−0.83, −0.26], P = 0.0002), with an I2 value of 68%. Subgroup analysis showed that patients with more active disease tended to benefit more from statin therapy (SMD −0.73, P = 0.01) than patients with moderate or low disease activity (SMD −0.38, P = 0.03). Statin therapy also significantly reduced tender joint counts, swollen joint counts, ESR, and CRP compared with placebo, but the reduction in HAQ score and VAS was not significant (P > 0.05). This meta-analysis suggested that statin therapy might be effective in the reduction of RA disease activity measured by DAS28, TJC, SJC, as well as ESR and CRP.Keywords
This publication has 31 references indexed in Scilit:
- Effect of rosuvastatin as adjuvant therapy to methotrexate on hematological parameters in patients with moderately-highly active rheumatoid arthritisJournal of Experimental and Integrative Medicine, 2013
- The Role of Simvastatin in the Therapeutic Approach of Rheumatoid ArthritisAutoimmune Diseases, 2013
- Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritisJournal of Lipid Research, 2011
- Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid ArthritisThe Journal of Rheumatology, 2010
- Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)Circulation Journal, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Successful treatment with fenofibrate, a peroxisome proliferator activated receptor α ligand, for a patient with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Cytokine Pathways and Joint Inflammation in Rheumatoid ArthritisNew England Journal of Medicine, 2001
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996